Blog
RSS FeedPosted by Michael Wonder on 17 Jul 2019
Majority of patients not asked for consent before being switched to a biosimilar, survey finds
17 July 2019 - The preliminary survey results showed that 52% of patients received a letter from hospital about switching to ...
Posted by Michael Wonder on 11 Jul 2019
Biosimilars continue to exhibit market failure
11 July 2019 - From their inception, biosimilars in the U.S. have faced headwinds. ...
Posted by Michael Wonder on 29 Jun 2019
Pfizer receives U.S. FDA approval for its first biosimilar, Zirabev (bevacizumab-bvzr)
28 June 2019 - Pfizer today announced the U.S. FDA has approved Zirabev (bevacizumab-bvzr), a biosimilar to Avastin (bevacizumab), for the ...
Posted by Michael Wonder on 24 Jun 2019
Forcing patients to switch to biosimilars puts them in uncharted waters
23 June 2019 - On May 27, the B.C. government announced a policy that will forcibly switch thousands of patients, ...
Posted by Michael Wonder on 24 Jun 2019
How big pharma suppresses ‘biosimilars’
23 June 2019 - Deals with insurers and pharmacy benefit managers at patient and taxpayer expense. ...
Posted by Michael Wonder on 24 Jun 2019
European Medicines Agency accepted first "China-Developed" biosimilar - Henlius HLX02 marketing authorisation application for review
21 June 2019 - First China-developed trastuzumab biosimilar accepted for MAA review by the EMA. ...
Posted by Michael Wonder on 20 Jun 2019
Combatting misinformation on biosimilars and preparing the market for them can save the U.S. billions
19 June 2019 - As politicians and policymakers debate effective ways to rein in rising health care costs, biosimilars represent ...
Posted by Michael Wonder on 18 Jun 2019
Advisory Council supports biosimilars in call for universal public drug coverage in Canada
17 June 2019 - A Canadian advisory council is recommending the use of biosimilars in a final report that lays ...
Posted by Michael Wonder on 14 Jun 2019
Ensuring innovation and competition for biologics leads to more timely products for patients
13 June 2019 - Today, the FDA approved the agency’s 20th biosimilar product, Kanjinti (trastuzumab-anns), for the treatment of patients with ...
Posted by Michael Wonder on 13 Jun 2019
Amgen wins FDA approval for Kanjinti injection for treatment of breast cancer, gastro-esophageal junction adenocarcinoma
13 June 2019 - U.S. FDA says Kanjinti (trastuzumab-anns) is biosimilar to Herceptin (trastuzumab). ...
Posted by Michael Wonder on 13 Jun 2019
Realigning incentives to optimise generic and biosimilar prescribing
13 June 2019 - Drug prices and their impact on total US health care expenditures are again front of mind ...
Posted by Michael Wonder on 11 Jun 2019
Should the FDA disclose new filings for drugs, biologics and biosimilars?
11 June 2019 - In 2010, the FDA issued draft recommendations on increasing the transparency of the FDA’s processes and ...
Posted by Michael Wonder on 11 Jun 2019
Systematic literature review calls economic impact of switching to biosimilars "uncertain"
10 June 2019 - Biosimilar drugs are intended by their developers to provide a cost-saving alternative to brand-name biologics, and ...
Posted by Michael Wonder on 11 Jun 2019
Biosimilar proposal for Medicare will depend on the details
11 June 2019 - Last month, the Biosimilars Forum released a proposal that it said could save the United States ...
Posted by Michael Wonder on 06 Jun 2019
Patients, physicians raise concerns with BC biosimilar non-medical switching policy
6 June 2019 - On 27 May, the Government of British Columbia announced a policy that will forcibly switch thousands ...